MORGANTOWN, W.Va. – Results from the first phase 3 HIV study to enroll only women show improved safety and efficacy of the drug Stribild over multi-pill antiretroviral drug regimens. Sally Hodder, M.D., director of the West Virginia Clinical and Translational Science Institute (WVCTSI) and associate vice president for clinical and translational science at West Virginia University, presented the findings at ASM’s 55th Interscience Conference of Antimicrobial Agents and Chemotherapy (ICAAC/ICC).
The results from the Women’s Antiretroviral Efficacy and Safety Study (WAVES), the first randomized, double-blind antiretroviral (ARV) trial to enroll only women, show that women receiving the drug Stribild had a statistically higher rate of HIV suppression compared to the group that received ritonavir-boosted atazanavir plus Truvada. Additionally, no one receiving Stribild developed resistant mutation to HIV-1, compared to three women in the comparator group.
Data from this study provides specific safety and efficacy profiles for women regarding two approved regimens. “The optimal selection of HIV treatment should be evidence-based, and WAVES provides clinical safety and efficacy data to assist women and their clinicians in the informed selection of antiretroviral treatment regimens,” Dr. Hodder said.
The complete announcement was issued by the American Society for Microbiology. The study was sponsored by Gilead Sciences, Inc.